Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Mostrar otras versiones (1)

The addition of vorinostat to lenalidomide/dexamethasone represents a novel combination therapy in multiple myeloma (MM), informed by laboratory studies suggesting synergy. This was a phase I, multicenter, open-label, non-randomized, dose-escalating study in patients with relapsed or relapsed and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegel, D S, Richardson, P, Dimopoulos, M, Moreau, P, Mitsiades, C, Weber, D, Houp, J, Gause, C, Vuocolo, S, Eid, J, Graef, T, Anderson, K C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944659/
https://www.ncbi.nlm.nih.gov/pubmed/24562384
http://dx.doi.org/10.1038/bcj.2014.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944659/
https://www.ncbi.nlm.nih.gov/pubmed/24562384
http://dx.doi.org/10.1038/bcj.2014.1

Ejemplares similares